Stability by Design (SbD): A proposal of application of Quality by Design (QbD) concept to physical stability as a control strategy
DOI:
https://doi.org/10.56511/JIPBS.2020.v7.i02.pp01-05Abstract
The ability to begin with the end in mind is a vital aspect of the Quality by Design (QbD) concept. The application of the concept to the process of pharmaceutical manufacturing, the first most requirement lies in developing a rather quality product. Also, the QbD concepts can be utilized in designing and developing product stability by assessing the reportable value of the given product as an analytical procedure for stability. Thus, a Stability Target Profile (STP) ought to be developed as it forms the foundation for stability development about the Stability Control Strategy (SCS). Contrary to the routine approaches, the SbD has to be initiated with a thorough comprehension of STP as well as risk evaluation for all the method variables that are likely to affect the response. An in-depth understanding of QbD will, therefore, be useful in the identification of the vulnerabilities and risks that relate to drug production, storage, and usage which will help in making informed choices and in return support the implementation of a control strategy.
Keywords:
Stability Control Strategy, Analytical Quality by Design, Stability Acceptable Design Region, Stability by Design and Quality by DesignDownloads
References
Lionberger RA, Lee SL, Lee L, Raw A, Yu LX: Quality by Design: concepts for ANDAs. American Association of Pharmaceutical Scientists 2008; 10(2):268 – 276.
Yu L. X., Amidon G., Khan MA, Hoag SW, Polli J, Raju GK and Woodcock J : Understanding pharmaceutical quality by design. American Association of Pharmaceutical Scientists Journal 2014; 16(4): 771 – 783. DOI:10.1208/s12248-014-9598-3.
Lionberger RA: FDA critical path initiatives: opportunities for generic drug development. American Association of Pharmaceutical Scientists 2008; 10(1):103 – 109.
Huang J, GoolcharranC and Ghosh K: A Quality by Design approach to investigate tablet dissolution shift upon accelerated stability by multivariate methods. European Journal of Pharmaceutics and Biopharmaceutics 2011; 78(1):141-150.
Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB and Arote R: Quality by Design approach: Regulatory need. Arabian Journal of Chemistry 2017; 10: S3412-S3425.
Swarali Goswami, Raja Chakraverty : A Review on Application of Quality by Design concept to Analytical Techniques. International Journal of Current Research In Health And Biological Sciences 2016; 1(3): 100-108.
Pramod K, Tahir MA, Charoo NA, Ansari SH and Ali J: Pharmaceutical product development: A quality by design approach. International Journal of Pharmaceutical Investigation 2016; 6:129-38.
Shashank Jain: Quality by design (QbD): A comprehensive understanding of implementation and challenges in pharmaceuticals development. International Journal of Pharmacy and Pharmaceutical Sciences 2014; 6(1):29-35.
Bhusnure O.G. et al: A Review on Application of Quality by Design Concept to Analytical Method Development. International Journal of Pharmacy and Pharmaceutical Research 2017; 10(1): 63-75.
N.V.V.S.S. Raman, Useni Reddy Mallu, Hanimi Reddy Bapatu: Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing. Journal of Chemistry 2015; Article ID 435129, 8 pages. https://doi.org/10.1155/2015/435129.
Balaji Jayagopal, Murugesh Shivashankar: Analytical Quality by Design – A Legitimate Paradigm for Pharmaceutical Analytical Method Development and Validation. Mechanics, Materials Science. Engineering Journal 2017; 9-10.2412.
USP Validation and verification expert panel. Stimuli to the revision process: Analytical control strategy. United States Pharmacopeial Convention (USP). Pharmacopeial forum 2016; 42(5).
USP Validation and verification expert panel 44(6) Stimuli to the Revision Process: Guidelines for Assessing and Controlling the Physical Stability of Pharmaceutical Raw Materials, Intermediates, and Dosage Forms. United States Pharmacopeial Convention (USP). Pharmacopeial forum 2018; 44 (6).
Lan Zhang, Shirui Mao: Application of quality by design in the current drug development. Asian Journal of Pharmaceutical Sciences 2017; 12(1): 1 – 8.
Food and Drug Administration. Guidance for industry. Drug stability guidelines. Rockville, MD: Food and Drug Administration; Dec 2008. https://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceE nforcement/GuidanceforIndustry/UCM051556.pdf
Food and Drug Administration. Draft guidance for industry. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) products — quality considerations. Rockville, MD: Food and Drug Administration; April 2018.https://www.fda.gov/downloads/drugs/guidances/ucm070573.pdf
Food and Drug Administration. Guidance for industry. Nasal spray and inhalation solution, suspension, and spray drug products — chemistry, manufacturing, and controls documentation. Rockville, MD: Food and Drug Administration ; July 2002. https://www.fda.gov/downloads/Drugs /GuidanceComplianceRegulatoryInformation/Guidance/ucm070575.pdf. Accessed 18 Jun 2018.
Food and Drug Administration. Guidance for industry. Liposome drug products — chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation. Silver Spring, MD: Food and Drug Administration; April 2018. https://www.fda.gov/downloads/drugs/guidances/ucm070570.pdf. Accessed 18 Jun 2018.
Food and Drug Administration. Guidance for industry. ANDAs: Stability testing of drug substances and products. Silver Spring, MD: Food and Drug Administration; June 2013. https://www.fda.gov/downloads/drugs /guidancecomplianceregulatoryinformation/guidances/ucm320590.pdf. Accessed 18 Jun 2018.
Food and Drug Administration. Guidance for industry. ANDAs: Stability testing of drug substances and products — questions and answers. Silver Spring, MD: Food and Drug Administration; May 2014
Food and Drug Administration. Guidance for industry. ANDAs: Pharmaceutical solid polymorphism — chemistry, manufacturing, and controls information. Rockville, MD: Food and Drug Administration; July 2007.
A. Refsdal et al: Cyber-Risk Management, Springer Briefs in Computer Science, DOI 10.1007/978-3-319-23570-7_9.
M. Deepaetal: Review on Quality by Design Approach for Analytical Method Development. Journal of Pharmacy Research 2017; 11(4):272-277.
Priyanka P. Pande, Sadikali F. Sayyad, Machindra J. Chavan, Sanjay R. Chaudhari: Quality by design in analytical method development and validation. J Environ Life Sci. 2017; 2(2): 39-45.
M. V. Ghica, L. Popa, G. Ş aramet, M. Leca, D. Lupuleasa, Ş t. Moisescu: Optimization of the pharmaceutical products and process design applying Taguchi quality engineering principles, Farmacia 2011; 59(3):321-328.
Jeremy Springall : H ow to Utilize Design of Experiment (DoE) Principles for Developing Robust Analytical Methods for QC Environments. American pharmaceutical review 2018.
J. Kochling, W. Wu, Y. Hua, Q. Guan, J. Castaneda-Merced: A platform analytical quality by design (AQbD) approach for multiple UHPLC-UV and UHPLC-MS methods development for protein analysis. Journal of Pharmaceutical and Biomedical Analysis 2016; 125: 130 – 139.
European Medicines Agency. Note for guidan ce on in-use stability testing of human medicinal products. London, England: The European Agency for the Evaluation of Medicinal Products; March 2001. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidel ine/2009/09/WC500003475.pdf. Accessed 18 Jun 2018.
European Medicines Agency. Guideline on stability testing for applications for variations to marketing authorization. London, England: European Medicines Agency; March 2014. http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2014/04/WC500164972.pdf. Accessed 18 Jun 2018.
Abhishek Singh, Zelalem Ayenew Worku & Guy Van den Mooter: Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opinion on Drug Delivery 2011; 8:10, 1361-1378.
European Medicines Agency. Guideline on the pharmaceutical quality of inhalation and nasal products. London, England: European Medicines Agency; Jun 2006. http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2009/09/WC500003568.pdf. Accessed 18 Jun 2018.
European Medicines Agency. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. London, England: European Medicines Agency; Feb 2013.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2013/03/WC500140351.pdf. Accessed 18 Jun 2018.
World Health Organization. Working document QAS/17.694. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. Geneva, Switzerland: World Health Organization; Jan 2017. http://www.who.int/medicines/areas/quality_safety/quality_assurance/stblt y-testing-APIsandFPPS-QAS17-694_12012017.pdf. Accessed 18 Jun 2018.
Ebenezer TO, Chioma C, Omoegbe IM: Instability of Cefpodoxime Proxetil Oral Suspension at Different Temperature Storage Conditions. J Pharmaceu. Pharmacol. 2017; 5(1): 6.
Tharwat Tadros: Application of rheology for assessment and prediction of the long-term physical stability of emulsions. Advances in Colloid and Interface Science 2004; 108 – 109:227-258.
Hongyu Wang, Yiwei Sun, Baixue Yang, Sanming Li: Association between the physical stability of flurbiprofen sus pension and the interaction of HPMC/SDS. Asian Journal of Pharmaceutical Sciences 2018; 13:63 – 71.
US Pharmacopeial Convention. Thermal Analysis 〈 891 〉 . In: USP 41 – NF
Rockville, MD: USP; 2018:6669 – 6673.
M.V. Ghica, M.G. Albu, M. Leca, L. Popa, Ş t. Moisescu: Design and optimization of some collagen - minocycline based hydrogels potentially applicable for the treatment of cutaneous wound infections. Pharmazie 2011; 66(11): 853 - 861 .
Acosta N, Sánchez E, Calderón L, Cordoba - Diaz M, Cordoba - DiazD, DomS, He ras Á: Physical Stability Studies of Semi - Solid Formulations from Natural Compounds Loaded with Chitosan Microspheres. Marine Drugs 2015; 1 3: 5901 - 5919.
Bjerknes K, HelmizadehZ, Brustugun J and Smistad G: Physical stability of moisture ‐ sensitive tablets stored in a canister or as a unit ‐ dose. J Pharm Pract Res 2017; 47:442-448. DOI: 10.1002/jppr.1306 .
US Pharmacopeial Convention. Tablet Friability 〈 1216 〉 . In: USP 41 – NF
Rockville, MD: USP; 2018:7634 – 7635.
Council of Europe. 2.9.7 Friability of uncoated tablets. In: European Pharmacopoeia 9.5. Strasbourg, France: Council of Europe 2018:312 – 313.
US Pharmacopeial Convention. Light Diffraction Measurement of Particle Size 〈 429 〉 . In: USP 41 – NF 36. Rockville, MD: USP; 2018:6206 – 6211.
US Pharmacopeial Convention. Water – Solid Interaction in Pharmaceutical Systems 〈 1241 〉 . In: USP 41 – NF 36. Rockville, MD: USP; 2018:7856 – 7860.
Council of Europe. 5.9 Polymorphism. In: European Pharmacopoeia 9.5. Strasbourg, France: Council of Europe 2018:719.
Published
How to Cite
Issue
Section
Copyright (c) 2020 Maher Abdulrazzaq Al-hakeem, Lăcrămioara Popa, Cristina Dinu-Pîrvu, Mihaela Violeta Ghica, Răzvan Prisada
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at